Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
London, 26 February 2026 – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025.
Said Darwazah, Chief Executive Officer (CEO) of Hikma, said:
“Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabled us to deliver Group revenue and profit growth in line with guidance, and resilient margins. While our Injectables business has experienced some challenges, we are taking clear steps to address these and we are confident in the longer-term prospects for this business.
The leadership changes that we are announcing today will enable us to execute the Group strategy with more agility and greater accountability. To support this, I will relinquish my Executive Chairman responsibilities and focus fully on being CEO.
We are confident in the guidance we have set for 2026, which assumes continued strong momentum in Branded and Hikma Rx and increased investment in Injectables. Looking ahead, our focus is on delivering sustainable profit growth. I remain optimistic for the future and am committed to returning to the out-performance we and our shareholders expect. Reflecting this, and our strong cash flow generation, we have increased our total dividend by 5% and are announcing a $250 million share buyback, which we will execute over the course of the year.”
|
Reported results (statutory) |
2025 $ million |
2024 $ million |
Change |
Constant currency[1] |
|
Revenue |
3,349 |
3,127 |
7% |
6% |
|
Operating profit |
542 |
612 |
(11)% |
(12)% |
|
Profit attributable to shareholders |
402 |
359 |
12% |
13% |
|
Cashflow from operating activities |
436 |
564 |
(23)% |
- |
|
Basic earnings per share (cents) |
182 |
162 |
12% |
13% |
|
Total dividend per share (cents) |
84 |
80 |
5% |
- |
|
Core results[2] (underlying) |
2025 $ million |
2024 $ million |
Change |
|
|
Core revenue |
3,349 |
3,156 |
6% |
5% |
|
Core operating profit |
741 |
719 |
3% |
3% |
|
Core EBITDA[3] |
853 |
824 |
4% |
3% |
|
Core profit attributable to shareholders |
503 |
495 |
2% |
2% |
|
Core basic earnings per share (cents) |
228 |
224 |
2% |
2% |
[1] Constant currency changes are derived after reported 2025 numbers translated using 2024 exchange rates, excluding price increases in the business resulting from the devaluation of currencies
[2] Core results throughout the document are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set out in Note 5 of this release. Core results are a non-IFRS measure. See page 15 for a reconciliation to reported IFRS results
[3] Core EBITDA is core operating profit before depreciation and software amortisation